Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Outsourcing PV: Core Competencies

Posted on December 7th, 2016 by



In a previous posting, we reviewed the drivers for the decision to outsource some or all pharmacovigilance (PV) activities. What activity to outsource is the next critical step. Continue reading “Outsourcing PV: Core Competencies” »

The Latest in Bioinformatics Solutions

Posted on December 5th, 2016 by

Pharma R&D


Next generation sequencing and other innovative developments in biological research are helping scientists understand disease and drug activity at a level never before thought possible. Continue reading “The Latest in Bioinformatics Solutions” »

Start-Up Spotlight: SiaMed’Xpress

Posted on December 2nd, 2016 by

Pharma R&D


SiaMed’Xpress is the company that we are focusing on in this week’s spotlight feature. Catherine Ronin, Chief Executive Officer of SiaMed’Xpress, talks about the start-up’s technology and research. Continue reading “Start-Up Spotlight: SiaMed’Xpress” »

Quality, Reproducibility, and Integrity in Early Research

Posted on November 30th, 2016 by

Pharma R&D

1st class

It is sad to hear about more paper retractions regarding early stage research with the R&D industry (1). Perhaps not surprisingly, the number of scientific publications being retracted for fraud and error has increased in recent years, at a faster rate than the rate of increased publications (2). Continue reading “Quality, Reproducibility, and Integrity in Early Research” »

The Costs of Irreproducible Biomedical Research

Posted on November 28th, 2016 by

Pharma R&D


Issues with reproducibility plague basic biomedical research. In a June 2015 study published in PLoS Biology, the authors suggested that U.S. researchers spend $28 billion a year on research that is irreproducible. Continue reading “The Costs of Irreproducible Biomedical Research” »

How Pharma Will Be Impacted by Trump’s Healthcare Reform Plans

Posted on November 25th, 2016 by

Pharma R&D


It has only been a couple of days since Donald Trump was elected President of the United States, but the pharmaceutical and biotech industries are already wondering what might be in store for them in 2017. Continue reading “How Pharma Will Be Impacted by Trump’s Healthcare Reform Plans” »

  1. 1
  2. 2
  3. 3
  4. …
  5. 26

About this Blog


The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.